CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a detailed exploration of how community pharmacies are evolving to meet…
AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025 AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October…
Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical company focused on innovative immuno-oncology therapies, announced today that it…
Oticara Reports Positive Phase 2 Results for Novel Nasal-Mucosa-Optimized Steroid Cream in Hard-to-Treat Post-Surgical Chronic Rhinosinusitis Oticara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), has announced encouraging outcomes from its Phase 2 OT-007B clinical…
WuXi Biologics Secures MSCI AAA ESG Rating for Third Consecutive Year, Reinforcing Global Sustainability Leadership WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced that it has achieved the highly esteemed AAA ESG rating…
AstraZeneca Expands U.S. Manufacturing Footprint with $4.5 Billion Virginia Facility, Creating 3,600 Jobs and Advancing Domestic Biopharmaceutical Production AstraZeneca has announced an expanded commitment to U.S. manufacturing with a $4.5 billion investment in a new state-of-the-art production facility in Virginia,…
bioAffinity Technologies Reports Record Third-Quarter 2025 Growth in CyPath® Lung Test Adoption, Driven by Expanding Clinical Use and Physician Confidence bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company pioneering noninvasive diagnostics for lung cancer and other lung diseases, has…
TCGX Closes Oversubscribed $1.3 Billion Fund III, Strengthening Its Position in Global Biopharma Investment TCG Crossover (“TCGX”), a leading global investment firm focused on the biotechnology and life sciences sector, announced the successful close of its third fund—TCGX Fund III—with…
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company committed to advancing innovative therapies for neurodegenerative diseases, today announced the pricing of its oversubscribed…
GSK Commits $30B To Boost US R&D, Manufacturing Operations The multi-billion, multi-year investment comes as many of GSK’s pharma peers pull away from the U.K., either suspending or completely canceling previous commitments.GSK will pump $30 billion into the U.S. over…
Choosing China: Akeso’s $3M Beginnings and the Rise of China’s Biotech Sector When Akeso was starting out some 13 years ago, the leadership team had $3 million and a bold goal to move China’s drug industry toward innovation. When Akeso…
Pioneering sustainable transatlantic transport to cut emissions in pharmaceutical supply chains Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using…